ANN ARBOR, Mich., Nov. 11, 2011 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), the leading developer of patient-specific, expanded multicellular therapies for the treatment of severe, chronic cardiovascular diseases, will hold a Research and Development Day for investors on November 17, 2011. The program will include a review of the clinical research program for ixmyelocel-T, the Company's investigational, patient-specific, expanded multicellular therapy for use in the treatment of severe, chronic cardiovascular diseases.
